Research Grants Awarded

The ACPMP Research Foundation has awarded $950,000 in the form of twenty research grants over the past eight years.  The following is a complete list of the research grants awarded through the ACPMP Research Foundation Research Grant Program:

2016 Grants Awarded
"The effect of Bromelain and N-acetylcysteine on appendiceal adenocarcinoma and pseudomyxoma peritonei in vitro and LS174T in vivo: development of a novel mucolytic agent and progression to a phase I/II study"
David L. Morris, MD, PhD, St George Hospital (Australia)
$50,000/2-year
This grant is issued in memory of Tyler Wright, Nancy Reed, Thomas Mullen, Shelley Mulvaney, Michael Dotta, Njoud Al-Qubaisi, Joanna Garvey, Bea Varra, Mark Fassio, William (Sonny) Hovan, Gail Reed, Mark Truelsen, and Frances Lewis
 
"Targeting the MEK-ERK pathway as a therapeutic option for Pseudomyxoma peritonei"
Venkatesh Govindarajan, PhD, Creighton University (Omaha, NE)
$50,000/2-year
This grant is issued in honor of Bob Worden, Rich Boozell, James Richter, Jeremy Kitzhaber, Scott Montgomery, and Dave Wood (with special thanks to the Gamma Zeta chapter of Kappa Kappa Gamma at the University of Arizona).
 

2015 Grants Awarded
"Developing a Novel Drug Delivery Platform for Targeting Hyaluronan"
Dr. Wilbur Bowne, Associate Professor in the Department of Surgery, Drexel University College of Medicine and Dr. Hao Cheng, Assistant Professor, Materials Science and Engineering, Drexel University, Philadelphia, PA, USA.
$50,000/2-year
Awarded in memory of Ann-Marie Barnes, Tobin Korsch, Caryl McClure, Gregory Giuliani, and Eleanor Culbertson.

"Cure4PMP — Genomic Biomarkers and Actionable Targets"
Kjersti Flatmark, MD, PhD, Radium Hospital, Oslo University Hospital Norway.
$50,000/2-year
Awarded in memory of Debbie Fink Green, Joanna Whyte, Dorothea Hadlick, Jay Walters, Irina Karnaugh, and Thomas Murphy.


2014 Grants Awarded
"T cell Immunotheraphy for Pseudomyxoma Peritonei"
Dr. Steven Katz of Roger Williams Medical Center, Providence, RI and Dr. Cherif Nazmy Boutros of the University of Maryland School of Medicine, Baltimore, MD.
$50,000/2-year
Awarded in memory of Doug Selmont, Keith Surges, Gail Arakelian, Daniel Cuoco, Robert McGee, Connie Grigsby, Linda Granbois, Kathleen DeFelice, Frances Lewis, and Stephen Costello

"Targeted Parallel Pathway Blockade as a Treatment Option for Pseudomyxoma Peritonei"
Dr. Venkatesh Govindarajan of Creighton University, Omaha, NE.
$50,000/2-year
Awarded in memory of Jim Disney, Barb Serbu, Denise Cannon, Bill Patchak, Patty McGroarty, Vincent Montagna, Frank Loughry, George Sheaffer, and Thomas Murphy


2013 Grants Awarded
Targeting Core Signaling Networks in Mucinous Adenocarcinoma of the Appendix”
Andrew Lowy, MD, Moores Cancer Center, University of California, San Diego
$50,000/2-year
Awarded in memory of PMPRF founder and former president, Lisa Luciano. 

"Carcinoembryonic Antigen – A Pro-Angiogenic Factor in Pseudomyxoma Peritonei – is a Potential Target for Therapy”
Principal Investigator: Peter Thomas, Ph.D. Surgery and Biomedical Sciences, Creighton University
$25,000/2-year
Awarded in memory of founding PMPRF board member and former treasurer, Michael Dvorsky.

"PMP: Biologic Foundations for New Treatment Options”
Principal Investigator: Venkatesh Govindarajan, Ph.D. Department of Surgery, Creighton University
$25,000/2-year
Awarded in memory of founding PMPRF board member and former treasurer, Michael Dvorsky.


2012 Grants Awarded
Genomic Analysis of Pseudomyxoma Peritonei and Cancer of the Appendix”
Edward Levine, MD, Wake Forest School of Medicine, North Carolina, USA
$50,000/2 year

Associated Publication: "Prognostic Molecular Subtypes of Low-Grade Cancer of the Appendix"

Significance of a Novel Genetic Alteration in Pseudomyxoma Peritonei”
Shigeki Sekine, MD, PhD, National Cancer Center Research Institute, Tokyo, Japan
$50,000/2 year

Associated Publications: (1) "Frequent GNAS mutations in low-grade appendiceal mucinous neoplasms." (Br J Cancer. Mar 5, 2013; 108(4): 951–958); (2) "Frequent lack of GNAS mutations in colorectal adenocarcinoma associated with GNAS-mutated villous adenoma." (Genes Chromosomes Cancer. 2014 Apr;53(4):366-72)


2011 Grants Awarded
Pseudomyxoma Peritonei: Prognostic Analysis of Micro-RNA and Other Biological Factors Using Tissue Microarray”
Marcello Deraco, MD, Director, Peritoneal Surface Malignancy Management Program, Fondazione IRCCS Instituto Nazionale Tumor (National Cancer Institute), Milano, Italy
$50,000/2 year
Research update from Marcello Deraco, MD, dated 8/7/13

Sequencing the Cancer Genome of Mucinous Adenocarcinoma of the Appendix”
Andrew Lowy,MD, Chief, Division of Surgical Oncology, Moores Cancer Center, University of California, San Diego, CA, USA
$50,000/2 year
Associated Publication: “Genome-wide mutational landscape of mucinous carcinomatosis peritonei of appendiceal origin.” (Genome Medicine 2014, 6:43)

Preclinical Targeting of the Goblet Cell Differentiation Pathway in Pseudomyxoma Peritonei”
Andrew Renehan, PhD, FRCS, Senior Lecturer in Cancer Studies and Surgery, School of Cancer and Enabling Sciences, University of Manchester, The Christie NHS Foundation Trust, Manchester, UK
$50,000/2 year
Research update from Andrew Renehan, PhD, FRCS, dated 8/7/13


2010 Grants Awarded
Treating PMP Using Small Molecule Inhibitors of Gel-forming Mucin Productions”
Zongsheng Guo, Ph.D., Division of Surgical Oncology, University of Pittsburgh, Pittsburgh, PA, USA
$50,000/2 year
Research update from Dr. Guo, dated 10/18/11
Associated Publications: (1) “Chronic anti-inflammatory drug therapy inhibits gel-forming mucin production in a murine xenograft model of human pseudomyxoma peritonei.” (Ann Surg Oncol. 2012 May;19(5):1402-9); (2) “Mucin as a therapeutic target in pseudomyxoma peritonei.” (J Surg Oncol. 2012 Dec; 106(7):911-7); (3) "Life after death: targeting high mobility group box 1 in emergent cancer therapies." (Am J Cancer Res. 2013; 3(1): 1–20); (4) "Mitogen-activated protein kinase inhibition reduces mucin 2 production and mucinous tumor growth." (Transl Res. 2015 Mar 28).

MicroRNA Profiling of Clinically Different Pseudomyxoma Peritonei Phenotypes”
Brendan Moran, MD, FRCS; Alex Mirnezami, PhD, FRCS, National Pseudomyxoma Peritonei Center-Basingstoke and North Hampshire Hospital NHS Foundation Trust, Basingstoke, UK --and-- The Cancer Research UK Center, Southampton General Hospital, Southampton, UK
$50,000/2 year
Research update from Dr. Mirnezami and Dr. Moran dated 11/29/11 

Translational Biology of Pseduomyxoma Peritonei”
Aaron A. Mansfield, MD; Robert Miller, MD, MSJulian Molina, MD, PhDFernando Quevado, MD, Department of Radiation Oncology and Division of Medical Oncology, Mayo Clinic, Rochester, MN
$50,000/2 year
Research update from Dr. Miller, dated 8/7/13
Associated Publication: “Concurrent MCL1 and JUN amplification in pseudomyxoma peritonei: a comprehensive genetic profiling and survival analysis.” (J Hum Genet. Mar 2014; 59(3): 124–128)


2009 Grants Awarded
Identification of molecular targets in pseudomyxoma peritonei via clonal analyses of metastases”
Herbert Zeh, MD, PhD; Co-Director, UPCI GI Oncology Program, Assistant Professor of Surgery, Division of Surgical Oncology, University of Pittsburgh, Pittsburgh, PA, USA
$50,000/2 year
Awarded in memory of Dutch Culbertson
Research update from Dr. Zeh, dated 5/4/12
Research update from Dr. Zeh, dated 11/8/11
Research update from Dr. Zeh, dated 1/3/11

Establishing Methods for Evaluating Anti-tumor Therapies for Treatment of Pseudomyxoma Peritonei Using Gene Profiles and Immortalized Cells”
Andrew Renehan, MD, PhD; Senior Lecturer in Cancer Studies and Surgery, Department of Surgery and Peritoneal Tumor Service, The Christie NHS Foundation Trust, University of Manchester, Manchester, UK
$50,000/2 year
Awarded in honor of Jerry Lewandowski
Research update from Dr. Renehan, dated 11/14/11
Research update from Dr. Renehan, dated 5/1/12
Associated publication: "Global gene expression in pseudomyxoma peritonei, with parallel development of two immortalized cell lines." (Oncotarget. 2015 Apr 13)

"Development of Animal Models for the Study of Pseudomyxoma and Evaluation of the Role of Anti-Angiogenesis in the Control of this Tumor"
Marc Pocard, MD, PhD; Professor of Surgery, Director of Research, National Institute of Health and Medical Research, Hopital Lariboisiere & Director, Angiogenesis and Translational Research Unit, Paris, France
$50,000/2 year
Awarded in honor of Mel R. Kurtz
Research update from Dr. Pocard, dated 10/7/10
Associated publication: “Orthotopic Animal Model of Pseudomyxoma Peritonei: An in Vivo Model to Test Anti-Angiogenic Drug Effects.” (Am J Pathol. 2014 May 9)

Please visit ACPMP Research Foundation Research Grant Program for more information.